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(41.4 versus 46.4, p = 0.01), while there was no difference in
MCS scores. Results from the regression analysis showed one
predisposing variable (unemployment), one enabling variable
(income < $0000), and three need variables (increasing number
of co-morbidities, severe joint pain, and severe motion limita-
tion) were signiﬁcantly associated with a lower PCS (model
Adjusted R2 = 0.38, p < 0.0001). No signiﬁcant association was
found between MCS scores and any variables from the model.
CONCLUSION: Patients with hemophilia had a lower PCS,
whereas MCS was comparable to the general U.S. popula-
tion. Unemployment, low income, increasing number of
co-morbidities, severe pain, and joint impairment negatively
impacted HRQoL. Preserving joint health by preventing joint
bleeding and arthropathy is important to maximize HRQoL in
patients with hemophilia.
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OBJECTIVE: Health-related quality of life (HRQL) of hemo-
philia patients with inhibitors has not been well documented in
the United States. This study aimed to measure the HRQL of
hemophilia patients with inhibitors and compare ﬁndings with
the HRQL of the U.S. general population. METHODS: Hemo-
philia patients with inhibitors (N = 90) who had participated in
a patient forum were mailed a survey which included the SF-12,
a validated generic HRQL instrument. Data were analyzed using
the standard SF-12 algorithms. Scores were assessed for each of
the eight HRQL domains and the two component summary
scores Physical (PCS) and Mental (MCS). These were compared
to those of the general population. RESULTS: Respondents
(n = 45, response rate = 50%) were predominantly male
(96.1%), and mean age was 20.7 years (SD = 18.8). The majority
is hemophilia type A (88.5%) and consider their disease
“serious.” Mean PCS of respondents was signiﬁcantly worse
(i.e., lower) than that of the general U.S. public (39.9 vs. 49.6:
p < 0.01). Four domain scores were signiﬁcantly lower among
respondents compared to the general U.S. public: physical
functioning, role physical, bodily pain and social functioning
(p < 0.01). Mean MCS was comparable, 49.9 vs. 49.6 (p = 0.72).
CONCLUSION: These ﬁndings conﬁrm results previously
shown in Europe (Gringeri et al 2005), that hemophilia patients
with inhibitors have a severely impaired physical HRQL, but
maintain a normal mental score compared with the general
population in the United States.
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OBJECTIVE: Anemia is a prevalent condition in patients who
are under treatment for cancer. Having an instrument that can
assess the impact of this potentially debilitating condition is
relevant to the patient and health care provider. Our objective
was to evaluate the psychometric properties of the FACT-An
for anemic cancer patients. METHODS: A comprehensive lit-
erature review was performed to summarize the psychometric
properties of the FACT-An and its subscales including the
FACT-Fatigue and the FACT-General for anemic cancer
patients. Published papers and abstracts were retrieved by
searching Medline 1992–2007, the Cochrane Library and
related websites. Relevant articles cited from these search ﬁnd-
ings were also reviewed. Key search terms included: anemia,
neoplasm, quality of life and erythropoetin. RESULTS: Of 272
citations, thirteen articles were included for critical review.
Nine papers reported satisfactory internal consistency (Cron-
bach’s alpha = 0.79–0.96) for all subscales except for non-
fatigue subscale (0.59–0.79). However, only two studies
reported adequate test-retest reliability (Intraclass correlation
coefﬁcient = 0.82–0.90). There was acceptable criterion validity
with signiﬁcant (p < 0.05) correlations (r = 0.18–0.40) between
the instrument and hemoglobin (Hb) levels. Each domains of
the FACT-An showed acceptable convergent validity with Piper
Fatigue questionnaire (r = 0.52–0.79) and Multidimensional
Fatigue Symptom Inventory (r = 0.49–0.89) and showed diver-
gent validity with Marlow-Crowne instrument, which measured
the social desirability (r = 0.04–0.18). The signiﬁcant (p < 0.05)
differences in the FACT-An scores between the patients who
had high Hb levels and low Hb levels showed satisfactory dis-
criminative validity. Minimally important differences ranged
4.24–7.0 were examined using anchor based method, distribu-
tion based method and regression analysis. The acceptable
responsiveness to change (effect 0.32 for the FACT-An; stan-
dardized response mean = 0.39 and Guyatt’s responsive-
ness = 0.55 for the Fatigue subscale) were investigated.
CONCLUSION: The FACT-An demonstrated overall accept-
able psychometric performances as a discriminative and evalu-
ative instrument for anemic patients, although evidence could
be strengthened with further research.
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OBJECTIVE: Treatment preferences of patients with hemophilia
and inhibitors have not been well documented. This study sought
to identify treatment attributes most important from a patient/
caregiver perspective in the United States. METHODS: A dis-
crete choice experiment was conducted to elicit treatment
preferences. Hemophilia patients with inhibitors or their caregiv-
ers completed a written survey that elicited preferences for treat-
ment features and levels synthesized from the medical literature
such as: risk of viral transmission, rise in inhibitor titer, reduction
in thromboembolic events, number of infusions, preparation
time, infusion time/volume, time required to stop bleeding/
alleviate pain, prophylaxis use, major surgery use, and medica-
tion cost. Best-worst case scaling was used to derive preferences.
Relative importance (RI) of preferences was modeled using a
multinomial logit function. RESULTS: Most respondents were
male (96.1%) with a mean age of 20.7 years (SD = 18.8). Most
patients were hemophilia type A (88.5%) and the majority
(88.5%) considered their disease “serious.” The three most
important patient-identiﬁed features were: time required to stop
bleeding (RI = 19.3), possibility that the level of inhibitor may
rise (RI = 14.3), and risk of contracting a virus from the product
(RI = 13.5). CONCLUSION: Inhibitor patients and caregivers
have speciﬁc treatment preferences based on product features.
Overall, patient preferences were similar to physicians (Lee,
2008), although patients placed more importance on the risk of
viral transmission, whereas physicians placed more on the time
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to alleviate pain. In contrast, other research (Mantovani, et al.,
2005) suggests greater importance of perceived viral safety
among both physicians and pharmacists relative to patients.
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OBJECTIVE: Assess the effects of tramadol ER once daily
versus placebo in patients with moderate to moderately severe
chronic pain due to osteoarthritis of the knee or hip.
METHODS: Data for this post-hoc analysis were from a
12-week, randomized, double-blind, placebo-controlled, once-
daily ﬁxed dose-study of tramadol ER (100 mg–300 mg).
Patients completed the WOMAC questionnaire at baseline and
weeks 1, 2, 3, 6, 9 and 12. Items in each WOMAC
subscale—pain (5-items), physical functioning (17-items) and
stiffness (2-items) were combined and normalized from 0-to
100. The minimum clinically important difference (MCID) set
at ten points improvement was determined from the literature.
Mean subscale scores, percent mean change from baseline and
the proportion of patients achieving a MCID at week 1 and 12
were assessed. RESULTS: A total of 809 patients were analyzed
(604-tramadol ER; 205-placebo). Both cohorts had similar
demographic and clinical characteristics at baseline. At week 1,
mean change in WOMAC global and subscale scores from
baseline for tramadol ER and placebo ranged from 12–16 and
7–10 points, respectively. Signiﬁcantly higher proportion of tra-
madol ER treated patients achieved MCID versus placebo
(p < 0.05) as early as week 1 except in the stiffness subscale. By
week 12, mean change for each subscale and total WOMAC
global score for tramadol ER treated patients were signiﬁcantly
greater versus placebo (p < 0.01), however, only higher doses
(200–300 mg) of tramadol ER treated patients achieved MCID
versus placebo (p < 0.01)On pain subscale, signiﬁcantly higher
proportion of patients treated with tramadol ER 100 mg
achieved MCID versus placebo at week 1 and 12 (p < 0.05).
CONCLUSION: This analysis showed that treatment with tra-
madol ER in patients with chronic pain extended to improve-
ments in physical function and stiffness as demonstrated by
achieving MCID in all WOMAC scores.
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OBJECTIVE: To assess the psychometric properties of the Power
of Food Scale (PFS) in diverse populations of obese and non-
obese individuals. METHODS: Data were obtained from adults
in a clinical trial for a weight management drug (n = 1739; mean
body mass index [BMI] [SD] = 38.6 [6.7]) and a web-based
survey (n = 1275; overweight and obese [BMI 27–76 kg/m2] and
non-obese [BMI 18–27 kg/m2]). Exploratory and conﬁrmatory
factor analyses were employed to discover the structure of PFS
using the clinical data. The model developed was then tested
using data from the web-based survey. The relationship between
PFS domains and BMI was also examined. Logistic regression
was used in the web-based survey to evaluate the association
between obese status and PFS scores. RESULTS: Psychometric
assessment of data from the clinical study indicated that the scale
was best represented by a 3-factor, 2nd-order model—three
domains and a composite domain (average of the three
domains)—which was conﬁrmed within the web-based survey
(Bentler’s Comparative Fit Index: 0.92 and 0.91, respectively).
Cronbach’s alpha for both data sets were high, ranging from
0.81–0.94 (three domains and a composite domain score). The
relationships between BMI and each domain were subtle and
approximately linear. An increase of one point in a PFS domain
score increased the odds of being obese by 1.6–2.4 times
(depending on the domain; domain scores range from 1 to 5).
CONCLUSION: The structure of PFS is represented by a 3
factor, 2nd-order model with three domains (Food Available,
Food Present, and Food Tasted) and a composite of them. This
structure has high internal consistency and reliability, relates to
BMI, and distinguishes between obese and non-obese subjects.
The data indicate that the PFS can be used to evaluate the effects
of treatment on patient perception of the power of food in trials
of obese patients.
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OBJECTIVE: Prior to use in an international study collecting
data from haemophiliacs, the Haemo-QoL and Haem-A-QoL
underwent linguistic validation in 17 languages. Whilst the origi-
nal Haemo-QoL was developed in British English, the Haem-A-
QoL had been developed in Italian. For the purposes of linguistic
validation, an English version of the latter was used as a basis for
the translations. Seven distinct versions exist: an adult form
(Haem-A-QoL) and child self-report and parent proxy versions
(Haemo-QoL) for 3 distinct age groups (4–7, 8–12, 13–16 years).
A rigorous methodology was required to ensure conceptual
equivalence and cultural relevance across different languages.
METHODS: For languages where no translation existed, the
process was conducted by a specialist in each target country
using the following standardized methodology: 1) two forward
translations by professional translators, native speakers of the
target language and ﬂuent in English; 2) comparison and recon-
ciliation of the translations by the specialist in the target country;
3) backward translation by a native English speaker; 4) compari-
son of source and backward version; 5) review by the developer
for a selection of languages; creation of the different forms of the
instrument; and 6) review by a clinician. Existing translations
were integrated into the process as appropriate. RESULTS:
Besides the challenge of ensuring conceptual equivalence with the
original and cultural appropriateness, the translation process
revealed two additional difﬁculties. When translating an expres-
sion, appropriate terms had to be found for each age group
whilst maintaining consistency across all versions of the same
language. CONCLUSION: The language versions of Haemo-
QoL and Haem-A-QoL were established according to a rigorous
translation methodology aiming to ensure conceptual equiva-
lence across different language versions to facilitate international
comparison and pooling of data. The linguistic validation
process as a whole supports the advantage of integrating inter-
national feedback on concepts and wording before a question-
naire is ﬁnalized.
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